Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial-Reference-Cited by-同舟云学术

Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial

Published:2019-02 Issue:1 Volume:52 Page:35-44
ISSN:1684-1182
Container-title:Journal of Microbiology, Immunology and Infection
language:en
Short-container-title:Journal of Microbiology, Immunology and Infection

Author:

Yuan Jinyi,Mo Biwen,Ma Zhuang,Lv Yuan,Cheng Shih-Lung,Yang Yanping,Tong Zhaohui,Wu Renguang,Sun Shenghua,Cao Zhaolong,Wu Jufang,Zhu Demei,Chang Liwen,Zhang Yingyuan,Zhao Li,Wang Xiongbiao,Wang Xuefen,Wang Dexi,Li Xiangyang,Peng Yiqiang,Liang Yongjie,Liu Hua,Xiao Zuke,Lv Xiaoju,Wu Shiman,Dai Yuanrong,Huang Yijiang,Hu Zhenghong,Qiu Chen,Li Xi,Zhang Suiyang,Li Wenpu,Liu Shuang,Shi Yi,Xiong Chang,Kuang Jiulong,Xiu Qingyu,Cui Shehuai,Li Jianguo,Lin Qichang,Huang Wenxiang,Wan Yixin,Qimanguli ,Shen Ce,Xiao Yi,Wu Xiaoju,Chuang Yin Ching,Perng Wann Cherng,Tsao Shih-Ming,Hsu Jeng-Yuan,Wang Chin-Chou,Wang Jen-Hsien,Yeh Pen-Fang,Lin His-Hsun,Kuo P.H.,Lin Ming-Shian,Su Wei-Juin

Funder

Major Research and Development Project of Innovative Drugs

Ministry of Science and Technology of China

TaiGen Biotechnology Co., Ltd.

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,General Medicine,Immunology and Allergy

Reference25 articles.

1. Increasing burden of community-acquired pneumonia leading to hospitalisation, 1998–2014;Quan;Thorax,2016

2. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality;Ewig;Thorax,2009

3. Pneumococcal infection in adults: burden of disease;Drijkoningen;Clin Microbiol Infect,2014

4. Clinical and economic burden of community-acquired pneumonia among adults in Europe;Welte;Thorax,2012

5. Community-acquired Moraxella catarrhalis bacteremic pneumonia: two case reports and review of the literature;Ariza-Prota;Case Rep Pulmonol,2016

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients;International Journal of Antimicrobial Agents;2024-08

2. Treatment of MRSA Infection: Where are We?;Current Medicinal Chemistry;2024-08

3. Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis;Journal of General Internal Medicine;2024-02-15

4. Schematic-portfolio of potent anti-microbial scaffolds targeting DNA gyrase: Unlocking ways to overcome resistance;International Journal of Biological Macromolecules;2024-01

5. In vitro pharmacodynamics of nemonoxacin and other antimicrobial agents against Mycoplasma pneumoniae;Microbiology Spectrum;2023-12-12